Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,896,940
  • Shares Outstanding, K 142,335
  • Annual Sales, $ 267,590 K
  • Annual Income, $ 129,090 K
  • 60-Month Beta 1.43
  • Price/Sales 21.90
  • Price/Cash Flow 38.74
  • Price/Book 50.20
Trade HALO with:

Options Overview Details

View History
  • Implied Volatility 50.83%
  • Historical Volatility 24.55%
  • IV Percentile 35%
  • IV Rank 35.82%
  • IV High 74.70% on 03/05/21
  • IV Low 37.52% on 09/03/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 122
  • Volume Avg (30-Day) 319
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,206
  • Open Int (30-Day) 2,029

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.44
  • Number of Estimates 4
  • High Estimate 0.56
  • Low Estimate 0.39
  • Prior Year 0.25
  • Growth Rate Est. (year over year) +76.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.00 +4.93%
on 08/26/21
43.38 -3.25%
on 09/08/21
+1.27 (+3.12%)
since 08/23/21
3-Month
37.80 +11.03%
on 08/19/21
46.62 -9.97%
on 07/02/21
-1.16 (-2.69%)
since 06/23/21
52-Week
25.17 +66.75%
on 09/24/20
56.40 -25.59%
on 02/24/21
+16.09 (+62.17%)
since 09/23/20

Most Recent Stories

More News
Halo Collective Today Announces the Completion of its At-the-Market Offering

Not for Distribution to U.S. Newswire Services or For Dissemination in the United States

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)
Halo Collective's Bophelo Bioscience & Wellness Signs Distribution Agreement with Cantourage GmbH for Rapidly Growing European Market

COMTEX_393400375/2669/2021-09-15T16:10:29

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)
Halozyme to Participate in the 2021 Cantor Virtual Global Healthcare Conference

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that , senior vice president and chief financial officer, will present at the 2021 Cantor Virtual Global Healthcare Conference...

HALO : 41.97 (+1.30%)
Halo Collective Announces Official Launch of Two Premium Cannabis Strains in Oregon with DNA Genetics

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)
Halo Collective Acquires Pistil Point Indoor Facility

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/All figures in USD, unless stated otherwise

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)
/R E P E A T -- Halo Collective Begins Construction of Dispensary in Westwood, Los Angeles/

First of Three Southern California Locations Targeted to Open in Fourth Quarter 2021

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)
Halo Collective Begins Construction of Dispensary in Westwood, Los Angeles

First of Three Southern California Locations Targeted to Open in Fourth Quarter 2021

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)
Halozyme Therapeutics (HALO) Up 4.2% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HALO : 41.97 (+1.30%)
/R E P E A T -- Halo Collective Announces Record Monthly Net Revenue of $3.9 Million in August/

/Not for Distribution to U.S. Newswire Services or For Dissemination in the United States/ All figures in USD

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)
Halo Collective Announces Record Monthly Net Revenue of $3.9 Million in August

/Not for Distribution to U.S. Newswire Services or For Dissemination in the United States/ All figures in USD

HALO : 41.97 (+1.30%)
HCANF : 0.0315 (+0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company's broad product development portfolio, including expected...

See More

Key Turning Points

3rd Resistance Point 42.94
2nd Resistance Point 42.50
1st Resistance Point 42.24
Last Price 41.97
1st Support Level 41.54
2nd Support Level 41.10
3rd Support Level 40.84

See More

52-Week High 56.40
Fibonacci 61.8% 44.47
Last Price 41.97
Fibonacci 50% 40.78
Fibonacci 38.2% 37.10
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar